At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 460 enrolled
Drug / intervention
LIK066 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo
In Brief
A Phase 2 clinical trial evaluating LIK066 and Placebo for Obesity and Overweight. Completed, enrolled 460 participants across 83 sites in 7 countries.
Detailed Summary
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesAustria, Canada, Czechia, Hungary, Slovakia, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionMar 2018
Study CompletionAug 2018
TodayJul 2026
First PostedApr 4, 2017
Enrollment StartMay 6, 2017
Primary CompletionMar 2, 2018
Study CompletionAug 2, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.2 years ago
Interventions
LIK066drug
LIK066 will be supplied in different doses as tablets to be taken orally.
Placebodrug
Placebo